Genetic Discovery to Therapeutic Target (2019)

Neuroscientists Jordan Follett and Emil Gustavsson from the University of British Columbia outlined the genetics of Parkinson's disease, focusing on how genetic data aids diagnosis and prognosis. The talk detailed approaches like association and familial studies and highlighted various genetic mutations linked to the disease. The discussion delved into leveraging genetic information to understand disease progression and identify potential therapies. Additionally, it emphasized the significance of genetic causes in Parkinson's, urging more homogeneous disease forms in trials to accurately gauge treatment effectiveness. Specific genes like VPS35 and DNAJC13 were explored for their role in neuronal protein trafficking, utilizing mouse models to study their impact on neuronal function and behavior.

Researchers found a mutation in the VPS35 gene that alters dopaminergic neurons and dopamine transporters, offering potential treatment avenues for VPS35-associated diseases. The mutation affected dopamine transport, resulting in altered protein levels. However, a specific drug normalized dopamine levels and improved behavior in mutant mice after seven days of treatment, suggesting the possibility of using existing compounds as a treatment for VPS35-associated diseases.

View the video slides accompanying this presentation by clicking here.

**Disclaimer: These sessions are designed to provide general education and are not intended for individual advice and/or clinical care. The information conveyed in this recording was accurate at the time of presentation.**